dc.contributor.author | Harakeh S. |
dc.contributor.author | Diab-Assaf M. |
dc.contributor.author | Niedzwiecki A. |
dc.contributor.author | Khalife J. |
dc.contributor.author | Abu-El-Ardat K. |
dc.contributor.author | Rath M. |
dc.contributor.editor | |
dc.date | 2006 |
dc.date.accessioned | 2017-10-03T15:43:36Z |
dc.date.available | 2017-10-03T15:43:36Z |
dc.date.issued | 2006 |
dc.identifier | 10.1016/j.leukres.2005.11.027 |
dc.identifier.isbn | |
dc.identifier.issn | 01452126 |
dc.identifier.uri | http://hdl.handle.net/10938/12525 |
dc.description.abstract | The effects of a novel nutrient formulation Epican Forte (EF) were evaluated on proliferation and induction of apoptosis using non-cytotoxic concentrations against HTLV-1 positive (HuT-102 andamp; C91-PL) and negative (CEM andamp; Jurkat) cells. EF showed anti-proliferative effect as determined by MTT assay and TGF mRNA protein expression using RT-PCR. EF resulted in the down-regulation of TGF-α and an up-regulation in TGF-β2. EF caused a significant increase in apoptotic cells in the preG1 phase. These results were confirmed using Cell Death ELISA and Annexin V-FITC. Induction of apoptosis was caused by an up-regulation of p53, p21 and Bax protein levels and a down-regulation of Bcl-2α protein expression level. © 2005 Elsevier Ltd. All rights reserved. |
dc.format.extent | |
dc.format.extent | Pages: (869-881) |
dc.language | English |
dc.publisher | OXFORD |
dc.relation.ispartof | Publication Name: Leukemia Research; Publication Year: 2006; Volume: 30; no. 7; Pages: (869-881); |
dc.relation.ispartofseries | |
dc.relation.uri | |
dc.source | Scopus |
dc.subject.other | |
dc.title | Apoptosis induction by Epican Forte in HTLV-1 positive and negative malignant T-cells |
dc.type | Article |
dc.contributor.affiliation | Harakeh, S., Department of Biology, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation | Diab-Assaf, M., Department of Biology, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation | Niedzwiecki, A., Dr. Rath Research Institute, Santa Clara, CA, United States |
dc.contributor.affiliation | Khalife, J., Department of Biology, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation | Abu-El-Ardat, K., Department of Biology, American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation | Rath, M., Dr. Rath Research Institute, Santa Clara, CA, United States |
dc.contributor.authorAddress | Harakeh, S.; Department of Biology, American University of Beirut, Beirut, Lebanon; email: sharakeh@gmail.com |
dc.contributor.authorCorporate | University: American University of Beirut; Faculty: Faculty of Arts and Sciences; Department: Biology; |
dc.contributor.authorDepartment | Biology |
dc.contributor.authorDivision | |
dc.contributor.authorEmail | sharakeh@gmail.com |
dc.contributor.faculty | Faculty of Arts and Sciences |
dc.contributor.authorInitials | Harakeh, S |
dc.contributor.authorInitials | Diab-Assaf, M |
dc.contributor.authorInitials | Niedzwiecki, A |
dc.contributor.authorInitials | Khalife, J |
dc.contributor.authorInitials | Abu-El-Ardat, K |
dc.contributor.authorInitials | Rath, M |
dc.contributor.authorOrcidID | |
dc.contributor.authorReprintAddress | Harakeh, S (reprint author), Amer Univ Beirut, Dept Biol, Beirut, Lebanon. |
dc.contributor.authorResearcherID | Harakeh, Steve-K-5709-2012 |
dc.contributor.authorUniversity | American University of Beirut |
dc.description.cited | Agarwal A, 2004, AM J PATHOL, V164, P1683, DOI 10.1016-S0002-9440(10)63727-3; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006-abbi.2000.1742; Ahn WS, 2003, DNA CELL BIOL, V22, P217, DOI 10.1089-104454903321655846; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056-NEJM199901143400204; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172-JCI6863; Cascinu S, 2000, CANCER INVEST, V18, P411, DOI 10.3109-07357900009032811; Chen JJ, 2004, BJU INT, V93, P1082, DOI 10.1111-1464-410X.2004.04785.x; CHUBINSKAYA SG, 1989, VOP MED KHIM, V35, P30; Cooke JP, 1997, ANNU REV MED, V48, P489; Dong Y, 2003, CANCER RES, V63, P52; Dunker N, 2002, GASTROENTEROLOGY, V122, P1364, DOI 10.1053-gast.2002.32991; Fleming J, 2001, NUTR CANCER, V40, P42, DOI 10.1207-S15327914NC401_9; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002-1097-0142(196504)18:4522::AID-CNCR28201804183.0.CO;2-J; Gansauge S, 1998, CELL GROWTH DIFFER, V9, P611; Gopee NV, 2004, TOXICOL SCI, V78, P204, DOI 10.1093-toxsci-ktb072; Guchelaar HJ, 1998, CANCER CHEMOTH PHARM, V42, P77, DOI 10.1007-s002800050788; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016-S0003-9861(02)00668-9; Harakeh S, 2004, CHEM-BIOL INTERACT, V148, P101, DOI 10.1016-j.cbi.2004.05.002; Harakeh S, 1995, NUTRITION, V11, P684; HARAKEH S, 1990, P NATL ACAD SCI USA, V87, P7245, DOI 10.1073-pnas.87.18.7245; Harakeh S, 1997, AIDS RES HUM RETROV, V13, P235, DOI 10.1089-aid.1997.13.235; HARAKEH S, 1994, CHEM-BIOL INTERACT, V91, P207, DOI 10.1016-0009-2797(94)90041-8; HARAKEH S, 1991, AM J CLIN NUTR, V54, pS1231; Harakeh Steve, 1994, Journal of Nutritional Medicine, V4, P393, DOI 10.3109-13590849409003588; Hare Y, 2001, GREEN TEA HLTH BENEF; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006-bbrc.2001.5293; Holt PR, 1998, JAMA-J AM MED ASSOC, V280, P1074, DOI 10.1001-jama.280.12.1074; Ip C, 2001, ANTICANCER RES, V21, P863; Jamison JM, 2004, BIOCHEM PHARMACOL, V67, P337, DOI 10.1016-j.bcp.2003.08.040; Kampman E, 2000, CANCER CAUSE CONTROL, V11, P459, DOI 10.1023-A:1008914108739; Kanai M, 2001, GASTROENTEROLOGY, V121, P56, DOI 10.1053-gast.2001.25544; Kawakami K, 2004, CLIN CANCER RES, V10, P5264, DOI 10.1158-1078-0432.CCR-04-0314; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084-jem.163.5.1037; Kinscherf R, 1998, FASEB J, V12, P461; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159-000068711; Li HC, 2000, JPN J CANCER RES, V91, P34; Liu MJ, 2005, CANCER CHEMOTH PHARM, V55, P79, DOI 10.1007-s00280-004-0849-3; Maramag C, 1997, PROSTATE, V32, P188, DOI 10.1002-(SICI)1097-0045(19970801)32:3188::AID-PROS53.0.CO;2-H; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182-blood-2002-01-0151; Morini M, 1999, INT J BIOL MARKER, V14, P268; MORTENSEON MM, 1986, J SURG RES, V114, P302; OKAZAKI I, 1992, J LAB CLIN MED, V120, P908; Ostrakhovitch EA, 2004, ARCH BIOCHEM BIOPHYS, V423, P351, DOI 10.1016-j.abb.2004.01.004; Rath M, 1992, ORTHOMOL MED, V7, P17; RATH M, 1991, J ORTHOMOL MED, V7, P17; Reddy VG, 2001, BIOCHEM BIOPH RES CO, V282, P409, DOI 10.1006-bbrc.2001.4593; Roomi MW, 2005, IN VIVO, V19, P179; Roomi MW, 2005, BREAST CANCER RES, V7, pR291, DOI 10.1186-bcr989; ROOMI MW, 2005, ONCOL REP, V12, P421; Roomi MW, 2005, MED ONCOL, V22, P129, DOI 10.1385-MO:22:2:129; Roomi MW, 2005, ONCOL REP, V13, P253; ROOMI MW, 2003, CANC OVERVIEW CELL M; Roomi MW, 2004, JANA, V7, P40; ROY M, 2003, MUTAT RES, V524, P33; SIMEONE AM, 2002, MOL CANCER THER, V1, P1366; Slattery ML, 1999, AM J EPIDEMIOL, V150, P869; Sun ZY, 2002, BBA-PROTEIN STRUCT M, V1596, P182, DOI 10.1016-S0167-4838(02)00233-9; Swede H, 2003, CANCER EPIDEM BIOMAR, V12, P1248; TOSETTI F, 2002, FASEB J, V16, P12; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074-jbc.274.37.26321; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007-BF00918135; Wolf Federica I., 1999, Frontiers in Bioscience, V4, pd607, DOI 10.2741-Wolf; Wu K, 2002, J NATL CANCER I, V94, P437, DOI 10.1093-jnci-94.6.437; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074-jbc.M101143200; Zhong WX, 2001, CANCER RES, V61, P7071 |
dc.description.citedCount | 16 |
dc.description.citedTotWOSCount | 16 |
dc.description.citedWOSCount | 16 |
dc.format.extentCount | 13 |
dc.identifier.articleNo | |
dc.identifier.coden | LERED |
dc.identifier.pubmedID | 16427125 |
dc.identifier.scopusID | 33744526743 |
dc.identifier.url | |
dc.publisher.address | THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND |
dc.relation.ispartofConference | |
dc.relation.ispartofConferenceCode | |
dc.relation.ispartofConferenceDate | |
dc.relation.ispartofConferenceHosting | |
dc.relation.ispartofConferenceLoc | |
dc.relation.ispartofConferenceSponsor | |
dc.relation.ispartofConferenceTitle | |
dc.relation.ispartofFundingAgency | |
dc.relation.ispartOfISOAbbr | Leuk. Res. |
dc.relation.ispartOfIssue | 7 |
dc.relation.ispartOfPart | |
dc.relation.ispartofPubTitle | Leukemia Research |
dc.relation.ispartofPubTitleAbbr | Leuk. Res. |
dc.relation.ispartOfSpecialIssue | |
dc.relation.ispartOfSuppl | |
dc.relation.ispartOfVolume | 30 |
dc.source.ID | WOS:000238787600014 |
dc.type.publication | Journal |
dc.subject.otherAuthKeyword | Amino acids |
dc.subject.otherAuthKeyword | Antioxidants |
dc.subject.otherAuthKeyword | Apoptosis |
dc.subject.otherAuthKeyword | Ascorbic acid (AA) |
dc.subject.otherAuthKeyword | Epican Forte |
dc.subject.otherAuthKeyword | Epigallocatechin-3-gallate (EGCG) |
dc.subject.otherAuthKeyword | HTLV-1 |
dc.subject.otherAuthKeyword | Leukemia |
dc.subject.otherChemCAS | 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide, 298-93-1 |
dc.subject.otherChemCAS | fluorescein isothiocyanate, 25168-13-2, 27072-45-3, 3326-32-7 |
dc.subject.otherChemCAS | lipocortin 5, 111237-10-6 |
dc.subject.otherChemCAS | protein bcl 2, 219306-68-0 |
dc.subject.otherChemCAS | protein p21, 85306-28-1 |
dc.subject.otherChemCAS | transforming growth factor, 76057-06-2 |
dc.subject.otherChemCAS | Acetylcysteine, 616-91-1 |
dc.subject.otherChemCAS | Antineoplastic Agents |
dc.subject.otherChemCAS | Arginine, 74-79-3 |
dc.subject.otherChemCAS | Ascorbic Acid, 50-81-7 |
dc.subject.otherChemCAS | Catechin, 154-23-4 |
dc.subject.otherChemCAS | Copper, 7440-50-8 |
dc.subject.otherChemCAS | DNA, 9007-49-2 |
dc.subject.otherChemCAS | epigallocatechin gallate, 989-51-5 |
dc.subject.otherChemCAS | Lysine, 56-87-1 |
dc.subject.otherChemCAS | Manganese, 7439-96-5 |
dc.subject.otherChemCAS | Proline, 147-85-3 |
dc.subject.otherChemCAS | Selenium, 7782-49-2 |
dc.subject.otherChemCAS | Transforming Growth Factors, 76057-06-2 |
dc.subject.otherIndex | 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide |
dc.subject.otherIndex | antineoplastic agent |
dc.subject.otherIndex | epican forte |
dc.subject.otherIndex | fluorescein isothiocyanate |
dc.subject.otherIndex | lipocortin 5 |
dc.subject.otherIndex | messenger RNA |
dc.subject.otherIndex | protein Bax |
dc.subject.otherIndex | protein bcl 2 |
dc.subject.otherIndex | protein p21 |
dc.subject.otherIndex | protein p53 |
dc.subject.otherIndex | transforming growth factor |
dc.subject.otherIndex | transforming growth factor alpha |
dc.subject.otherIndex | transforming growth factor beta2 |
dc.subject.otherIndex | unclassified drug |
dc.subject.otherIndex | apoptosis |
dc.subject.otherIndex | article |
dc.subject.otherIndex | cancer cell culture |
dc.subject.otherIndex | cell cycle G1 phase |
dc.subject.otherIndex | cell death |
dc.subject.otherIndex | cell proliferation |
dc.subject.otherIndex | controlled study |
dc.subject.otherIndex | down regulation |
dc.subject.otherIndex | drug effect |
dc.subject.otherIndex | drug efficacy |
dc.subject.otherIndex | enzyme linked immunosorbent assay |
dc.subject.otherIndex | human |
dc.subject.otherIndex | human cell |
dc.subject.otherIndex | Human T cell leukemia virus 1 |
dc.subject.otherIndex | priority journal |
dc.subject.otherIndex | protein expression |
dc.subject.otherIndex | reverse transcription polymerase chain reaction |
dc.subject.otherIndex | statistical significance |
dc.subject.otherIndex | T lymphocyte |
dc.subject.otherIndex | upregulation |
dc.subject.otherIndex | Acetylcysteine |
dc.subject.otherIndex | Antineoplastic Agents |
dc.subject.otherIndex | Apoptosis |
dc.subject.otherIndex | Arginine |
dc.subject.otherIndex | Ascorbic Acid |
dc.subject.otherIndex | Catechin |
dc.subject.otherIndex | Cell Cycle |
dc.subject.otherIndex | Cell Line, Tumor |
dc.subject.otherIndex | Cell Proliferation |
dc.subject.otherIndex | Copper |
dc.subject.otherIndex | Dietary Supplements |
dc.subject.otherIndex | DNA |
dc.subject.otherIndex | Dose-Response Relationship, Drug |
dc.subject.otherIndex | Drug Screening Assays, Antitumor |
dc.subject.otherIndex | Enzyme-Linked Immunosorbent Assay |
dc.subject.otherIndex | Flow Cytometry |
dc.subject.otherIndex | Gene Expression Profiling |
dc.subject.otherIndex | Human T-lymphotropic virus 1 |
dc.subject.otherIndex | Humans |
dc.subject.otherIndex | Lysine |
dc.subject.otherIndex | Manganese |
dc.subject.otherIndex | Proline |
dc.subject.otherIndex | Reverse Transcriptase Polymerase Chain Reaction |
dc.subject.otherIndex | Selenium |
dc.subject.otherIndex | Sensitivity and Specificity |
dc.subject.otherIndex | Structure-Activity Relationship |
dc.subject.otherIndex | T-Lymphocytes |
dc.subject.otherIndex | Transforming Growth Factors |
dc.subject.otherKeywordPlus | GREEN TEA EXTRACT |
dc.subject.otherKeywordPlus | NF-KAPPA-B |
dc.subject.otherKeywordPlus | HUMAN-IMMUNODEFICIENCY-VIRUS |
dc.subject.otherKeywordPlus | PROSTATE-CANCER CELLS |
dc.subject.otherKeywordPlus | GROWTH-FACTOR-BETA |
dc.subject.otherKeywordPlus | CYCLE ARREST |
dc.subject.otherKeywordPlus | ASCORBIC-ACID |
dc.subject.otherKeywordPlus | IN-VITRO |
dc.subject.otherKeywordPlus | BREAST-CANCER |
dc.subject.otherKeywordPlus | COLON-CANCER |
dc.subject.otherWOS | Oncology |
dc.subject.otherWOS | Hematology |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |